An Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients With Pulmonary Arterial Hypertension [EXTENSION OF 700237724]

Trial Profile

An Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients With Pulmonary Arterial Hypertension [EXTENSION OF 700237724]

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2014

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Acronyms PHIRST-2
  • Sponsors Eli Lilly
  • Most Recent Events

    • 17 Jun 2014 Results published in the Internet Document.
    • 16 Jun 2014 New trial record
    • 01 Mar 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top